Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10868062 | 0.89 | MAPK1 (0.49) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL10869158 | 0.87 | MAPK1 (0.46) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| Alcohol SCHEMBL29046146 | 0.84 | KMT2A (0.50) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL4304201 | 0.83 | ALDH1A1 (0.42) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL29038695 | 0.83 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBL3MBTL1MAPK1 | |
| SCHEMBL7757481 | 0.82 | KMT2A (0.56) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL19172427 | 0.82 | KMT2A (0.56) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL14856230 | 0.82 | KMT2A (0.56) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL8564 | 0.82 | — | — | |
| SCHEMBL227313 | 0.82 | KMT2A (0.56) | MEN1CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114965307-A | Method for detecting potassium ion concentration through G-quadruplex DNA dimerization | 中国科学院大连化学物理研究所 | 2022-08-30 | — | — | CN | claimed |
| CN-114965307-A | Method for detecting potassium ion concentration through G-quadruplex DNA dimerization | 中国科学院大连化学物理研究所 | 2022-08-30 | — | — | CN | disclosed |
| US-11307206-B2 | Functionalized metal-labeled beads for mass cytometry | DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN (DE) | 2022-04-19 | — | — | US | disclosed |
| EP-3570034-A2 | FUNCTIONALIZED METAL-LABELED BEADS FOR MASS CYTOMETRY | Deutsches Rheuma-Forschungszentrum Berlin (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-20190331689-A1 | FUNCTIONALIZED METAL-LABELED BEADS FOR MASS CYTOMETRY | DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN (DE) | 2019-10-31 | — | — | US | disclosed |
| US-8535650-B2 | Drug delivery; bioavailability; mixture containing glycerides ,surfactant and stabilizer | SOLIGENIX, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-7829523-B2 | Method for stabilizing polypeptides lacking methionine | DOW PHARMACEUTICAL SCIENCES (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1460992-B1 | STABILIZED REVERSE MICELLE COMPOSITIONS AND USES THEREOF | DOR BIOPHARMA INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080139454-A1 | Method for stabilizing polypeptides lacking methionine | JPMORGAN CHASE BANK, N.A. | 2008-06-12 | — | — | US | disclosed |
| EP-1460992-A4 | STABILIZED REVERSE MICELLE COMPOSITIONS AND USES THEREOF | DOR BIOPHARMA INC (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2000076476-A1 | ADJUVANT-CONTAINING POLYMERIZED LIPOSOMES FOR ORAL, MUCOSAL OR INTRANASAL VACCINATION | ENDOREX CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000067779-A2 | POLYMERIZED LIPOSOMES FOR THE DELIVERY OF MAMMALIAN GROWTH HORMONE | ENDOREX CORPORATION (US) | 2000-11-16 | — | — | WO | disclosed |
| EP-1049759-A1 | NOVEL POLYMERIZABLE FATTY ACIDS, PHOSPHOLIPIDS AND POLYMERIZED LIPOSOMES THEREFROM | Orasomal Technologies, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6060082-A | PHOSPHOLIPID BILAYER HAVING COVALENTLY BONDED PHOSPHOLIPIDS, AN AQUEOUS CORE AND A LECTIN WHEREIN THE LECTIN IS ULEX EUROPEANS AGGLUTININ I. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6004534-A | POLYMERIZED LIPOSOMES WHICH HAVE BEEN MODIFIED, PREFERABLY ON THEIR SURFACE, TO CONTAIN MOLECULE OR LIGAND WHICH TARGETS SPECIFIC SITE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1999033940-A1 | NOVEL POLYMERIZABLE FATTY ACIDS, PHOSPHOLIPIDS AND POLYMERIZED LIPOSOMES THEREFROM | ORASOMAL TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5762904-A | Oral delivery of vaccines using polymerized liposomes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1995003035-A1 | POLYMERIZED LIPOSOMES WITH ENHANCED STABILITY FOR ORAL DELIVERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1995-02-02 | — | — | WO | disclosed |
| US-5272135-A | Method for the stabilization of methionine-containing polypeptides | CHIRON OPHTHALMICS, INC. (US) | 1993-12-21 | — | — | US | disclosed |
| WO-1992015614-A1 | METHOD FOR THE STABILIZATION OF METHIONINE-CONTAINING POLYPEPTIDES | CHIRON OPHTHALMICS, INC. (US) | 1992-09-17 | — | — | WO | disclosed |